Literature DB >> 9360515

Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition.

N Vahl1, N Møller, T Lauritzen, J S Christiansen, J O Jørgensen.   

Abstract

The acute effects of a single GH pulse have previously been studied in young males. It is, however, likely that both the metabolic effects and the pharmacokinetics of GH may differ between age groups and sexes. We studied 36 healthy, clinically nonobese adults of both sexes, who were divided into a young group (mean age, 29.6 yr) and an older group (mean age, 51.0 yr). On 2 separate occasions, they received an i.v. bolus of either GH (200 micrograms) or saline followed by blood sampling for 5 h. Glucose turnover was estimated by infusion of [3-3H]glucose, and indirect calorimetry was performed before and 2 h after the bolus infusions. Body composition (computed tomography scan and dual energy x-ray absorptiometry) was performed at baseline. Baseline levels of serum insulin-like growth factor I (IGF-I) was lower in older subjects, whereas circulating IGF-binding protein-1 and lipid intermediates were lower in males than in females. The area under the GH curve was lower in older subjects (young, 3978 +/- 1532 micrograms/L.24 h; older, 1144 +/- 79; P = 0.001), whereas the elimination half-life did not differ with age (young, 18.1 +/- 0.9 min; older, 16.4 +/- 0.8; P = NS). The MCR and apparent distribution volume of GH were higher in older subjects [MCR: young, 0.11 +/- 0.02 min/L; older, 0.19 +/- 0.01; P = 0.001; apparent distribution volume: young, 2.5 +/- 0.4 L; older, 4.5 +/- 0.3; P < 0.001). Both MCR and Vd correlated inversely with age and positively with indexes of adiposity. GH significantly increased lipid intermediates, but the response was higher in young subjects and males. By contrast, the ability of GH to acutely suppress IGF-binding protein-1 was more pronounced in older subjects and females. Serum levels of insulin and IGF-I did not differ significantly between GH and saline treatment groups. GH decreased the respiratory exchange ratio and increased resting energy expenditure, with no age or gender differences. A gradual decline over time in plasma levels and rate of turnover of glucose was recorded after both GH and saline. The following conclusions were reached. 1) The MCR and Vd of GH increase with age and correlate positively with fat mass. 2) Older subjects are responsive to the acute lipolytic effects of GH, but the response is higher in young subjects and in males. 3) Adipose tissue may be actively involved in the distribution and clearance of GH. 4) Age, sex, and body composition interact with GH in a complex manner, involving clearance, distribution, and metabolic actions of the hormone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360515     DOI: 10.1210/jcem.82.11.4388

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Motivations and methods for analyzing pulsatile hormone secretion.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Steven M Pincus
Journal:  Endocr Rev       Date:  2008-10-21       Impact factor: 19.871

2.  Growth hormone-releasing hormone is produced by adipocytes and regulates lipolysis through growth hormone receptor.

Authors:  F Rodríguez-Pacheco; C Gutierrez-Repiso; S García-Serrano; A Ho-Plagaro; J M Gómez-Zumaquero; S Valdes; M Gonzalo; J Rivas-Becerra; C Montiel-Casado; G Rojo-Martínez; E García-Escobar; E García-Fuentes
Journal:  Int J Obes (Lond)       Date:  2017-06-19       Impact factor: 5.095

3.  Complementary secretagogue pairs unmask prominent gender-related contrasts in mechanisms of growth hormone pulse renewal in young adults.

Authors:  Cacia Soares-Welch; Leon Farhy; Kristi L Mielke; Farid H Mahmud; John M Miles; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2005-01-05       Impact factor: 5.958

4.  Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.

Authors:  Iñaki F Trocóniz; Josep-María Cendrós; Concepción Peraire; Joaquim Ramis; Maria J Garrido; Paolo F Boscani; Rosendo Obach
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  The exercise-induced biochemical milieu enhances collagen content and tensile strength of engineered ligaments.

Authors:  Daniel W D West; Ann Lee-Barthel; Todd McIntyre; Baubak Shamim; Cassandra A Lee; Keith Baar
Journal:  J Physiol       Date:  2015-09-14       Impact factor: 5.182

Review 6.  Growth hormone, IGF-I and insulin and their abuse in sport.

Authors:  R I G Holt; P H Sönksen
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

Review 7.  The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations.

Authors:  Darlene E Berryman; Camilla A M Glad; Edward O List; Gudmundur Johannsson
Journal:  Nat Rev Endocrinol       Date:  2013-04-09       Impact factor: 43.330

8.  IGF-I improved bone mineral density and body composition of weaver mutant mice.

Authors:  Weiguo Yao; Jin Zhong; Jun Yu; Therry Warner; Tomica Bozic; Ping Ye; A Joseph D'Ercole; Janet M Hock; Wei-Hua Lee
Journal:  Growth Horm IGF Res       Date:  2008-06-11       Impact factor: 2.372

9.  Insulin and GH signaling in human skeletal muscle in vivo following exogenous GH exposure: impact of an oral glucose load.

Authors:  Thomas Krusenstjerna-Hafstrøm; Michael Madsen; Mikkel H Vendelbo; Steen B Pedersen; Jens S Christiansen; Niels Møller; Niels Jessen; Jens O L Jørgensen
Journal:  PLoS One       Date:  2011-05-03       Impact factor: 3.240

Review 10.  The influence of sex on pharmacokinetics.

Authors:  Janice B Schwartz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.